



Selenium Supplementation in Psoriasis Patients

Hadis Gerami; PhD candidate^{1,2}, Atie Sadat Khorasanian; MSc³ & Azadeh Lesani; PhD^{*4}

¹ Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;

² Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ³ Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; ⁴ Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.

ARTICLE INFO

EDITORIAL ARTICLE

Article history:

Received: 18 Mar 2022

Revised: 7 May 2022

Accepted: 7 Jun 2022

*Corresponding author

a_lesani@razi.tums.ac.ir

Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences.

Postal code: 14155/6117

Tel: +98 21 88955979

Psoriasis is an autoimmune skin disease known for inflammation and hyper-proliferation of epidermal keratinocytes (Luo *et al.*, 2020). 2-3% of the population suffer from psoriasis (Parisi *et al.*, 2013). Emotional distress in psoriasis patients impairs quality of their life. Moreover, they suffer from the burden of comorbidities like obesity, diabetes mellitus, metabolic syndrome (Armstrong *et al.*, 2013b), and hypertension (Armstrong *et al.*, 2013a) through the increase in psoriasis severity. The pathogenesis of psoriasis is not well understood yet. It is concluded from the interactions between genetic predisposition and the environmental risk factors, such as diet, alcohol consumption, stress, obesity, and smoking (Ricketts *et al.*, 2010). One pathogenesis of psoriasis is amplifying T-cells and dendritic cells from the immune system, which releases various pro-inflammatory cytokines and chemokines with simultaneous activation of growth factors (Al-Harbi *et al.*, 2020). Moreover, oxidative stress and

reactive oxygen species (ROS) production causes inflammation (Wacewicz *et al.*, 2017). High free radicals have harmful effects through structural changes on proteins, lipids, and nucleic acids. The increase in oxidants leads to active antioxidant defense mechanisms (Lobo *et al.*, 2010). Enzymatic antioxidant defense mainly includes glutathione peroxidase (containing selenium), superoxide dismutase (including copper and zinc as cofactors), and catalase (Armstrong *et al.*, 2011). Trace elements also play an essential role in immunologic and inflammatory reactions. Zinc and selenium influence the antioxidant structure of the human body. However, these vital elements act based on the normal physiological response of those enzymes elaborated in the antioxidant defense system (Fernández-Lázaro *et al.*, 2020). Selenium and selenoproteins regulate inflammation by changing eicosanoid production to anti-inflammation eicosanoid (Avery and Hoffmann, 2018). Although keratinization and melanin

formation are enzyme-dependent processes increased in patients with psoriasis (Chen *et al.*, 2019), the trace element deficiency in human body can decline the activity of the selenium-dependent enzyme in patients (Ricketts *et al.*, 2010). Furthermore, decreasing antioxidant blockade in the skin, and increasing free oxygen radicals create psoriatic plaques or lesions (Yildirim *et al.*, 2003). The treatment of psoriasis with mineral supplements (Ricketts *et al.*, 2010) and medicated shampoo containing selenium could prove beneficial (Verardino *et al.*, 2012).

The dietary habits among psoriasis patients were imbalanced. Previous epidemiological studies indicated a higher intake of saturated fatty acid (SFA), simple sugar, and alcohol; and a lower intake of proteins, fiber, and unsaturated fatty acids which exacerbate psoriasis, while the others such as low-calorie diet, gluten-free diet, vitamin D, vitamin B12, Omega-3-PUFAs, dietary fibers, selenium, or probiotic supplements ameliorate psoriasis (Ricketts *et al.*, 2010, Zuccotti *et al.*, 2018). There are contradictory findings about serum levels of trace elements and total antioxidant status in psoriasis patients. Studies demonstrated serum selenium level was lower among psoriasis patients compared with those in the control group (Kirit *et al.*, 2020, Waciewicz *et al.*, 2017); this indicates pro-antioxidant's imbalance among psoriasis. However, a meta-analysis showed some trace element (zinc, copper, not selenium) levels in a homeostatic imbalance in psoriasis patients compared with the control group (Chen *et al.*, 2019). The duration and severity of psoriasis could affect serum selenium concentration (Serwin *et al.*, 2003). Selenium deficiency can be considered a risk factor resulting in susceptibility to inflammatory skin diseases (Rayman, 2000). Selenium deficiency and overload could lead to cell injury (Rayman, 2000). Serum selenium level is related to plasma osteopontin level as an atherosclerosis predictor marker among psoriasis patients (Toossi *et al.*, 2015). Overexpression of osteopontin and low plasma levels of selenium are predictable factors for the incidence of psoriasis. The effect of selenium supplements has been investigated in some

randomized clinical trials. Fairris *et al.* studied 600 $\mu\text{g/day}$ selenium as selenium-enriched yeast for 12 weeks in comparison with 600 $\mu\text{g/day}$ selenium plus 600 IU vitamin E-enriched yeast and placebo group (Fairris *et al.*, 1989). In addition, Serwin *et al.* examined 200 $\mu\text{g/day}$ for 4 weeks with narrowband ultraviolet B therapy (Serwin *et al.*, 2006). However, these studies did not show significant improvement in Psoriasis Area and Severity Index (PASI). PASI is a typical score to measure severity in psoriasis patients. Oral administration of selenium (400 $\mu\text{g/day}$) did not indicate a significant change in proteins (P53, Fax, Bax, and Bcl-2) or a protective effect against skin damage by ultraviolet (DeSilva *et al.*, 2007). Although a double-blind placebo-controlled clinical study assessing 58 psoriasis patients revealed therapeutic effects of combined antioxidants, selenium (48 $\mu\text{g/day}$ for 30 – 35 day), vitamin E, and coenzyme Q10 showed a significant improvement in PASI and marker of oxidative stress (Kharaeva *et al.*, 2009). Selenium is a vital component of cellular antioxidant defenses, and it has protective effects against ultraviolet radiation-induced damage to skin cells (McKenzie, 2000) and ultraviolet B radiation-induced skin cancer in a murine model (Rafferty *et al.*, 2002). There is a need for better-designed studies with a proper dose of selenium and in combination with other antioxidants to assess the efficacy of selenium supplements in psoriasis patients. Selenium is a cofactor for thioredoxin reductase (Wadhvani *et al.*, 2016). It is also involved in 25 selenoprotein genes in the human genome, affecting immunomodulation, sperm motility, and preventing the risk of miscarriage (Rayman, 2000). Current evidence showed selenium nanoparticles (SeNPs) inhibit epidermal hyperplasia through anti-proliferative and anti-inflammatory activities. SeNPs have been identified as an anti-cancer agent (Pi *et al.*, 2013). In the animal model, SeNPs acted as an effective treatment in inflammation-driven disorders like arthritis, liver fibrosis, and nephropathy. Moreover, the anti-inflammatory activity of SeNPs and the reduction of inflammatory cytokines levels are known as the primary mechanisms of it (Yazdi *et al.*, 2015).

SeNPs as biological inertness may be the ideal therapy in psoriasis patients.

In summary, genetics and diet could play a critical role in prevention, improvement, treatment, and incidence of psoriasis. This inflammatory skin disease needs more trace elements which act in the antioxidant defense system; however, an overload of these trace elements could be harmful. A safe and appropriate dose of selenium in a patient with selenium deficiency could help to control the disease. Selenium deficiency is related to the severity and length of suffering from this disease. Long-term usage of comprehensive available treatment options in psoriasis patients could produce adverse effects. SeNPs, as safe nanomedicine, may have beneficial effects in the treatment of psoriasis patients. Further studies among psoriasis patients could provide more insights.

Authors' contributions

Gerami H, Khorasanian AS and Lesani A drafted the manuscript. A.L critically revised the manuscript and agree to be fully accountable for ensuring the integrity and accuracy of the work. All authors read and approved the final manuscript.

Conflict of interest

The authors of the study declared no conflict of interest.

References

- Al-Harbi NO, et al.** 2020. Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells. *European journal of pharmacology*. **877**: 173088.
- Armstrong AW, Harskamp CT & Armstrong EJ** 2013a. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. *Journal of hypertension*. **31** (3): 433-443.
- Armstrong AW, Harskamp CT & Armstrong EJ** 2013b. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. *Journal of the American Academy of Dermatology*. **68** (4): 654-662.

- Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN & Rutledge JC** 2011. Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. *Journal of dermatological science*. **63** (1): 1-9.
- Avery JC & Hoffmann PR** 2018. Selenium, Selenoproteins, and Immunity. *Nutrients*. **10** (9): 1203.
- Chen W, Zhou X & Zhu W** 2019. Trace Elements Homeostatic Imbalance in Psoriasis: a Meta-Analysis. *Biological trace element research*. **191** (2): 313-322.
- DeSilva B, et al.** 2007. Lack of effect of oral selenite on p53 associated gene expression during TL01 therapy of psoriasis patients. *Photodermatol photoimmunol photomed*. **23** (2-3): 98-100.
- Fairris GM, Lloyd B, Hinks L, Perkins PJ & Clayton BE** 1989. The effect of supplementation with selenium and vitamin E in psoriasis. *Annals of clinical biochemistry*. **26** (Pt 1): 83-88.
- Fernández-Lázaro D, et al.** 2020. The Role of Selenium Mineral Trace Element in Exercise: Antioxidant Defense System, Muscle Performance, Hormone Response, and Athletic Performance. A Systematic Review. *Nutrients*. **12** (6): 1790.
- Kharaeva Z, Gostova E, De Luca C, Raskovic D & Korkina L** 2009. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. *Nutrition*. **25** (3): 295-302.
- Kirmit A, et al.** 2020. Trace elements and oxidative stress status in patients with psoriasis. *Postepy dermatologii i alergologii*. **37** (3): 333-339.
- Lobo V, Patil A, Phatak A & Chandra N** 2010. Free radicals, antioxidants and functional foods: Impact on human health. *Pharmacogn Rev*. **4** (8): 118-126.
- Luo Y, et al.** 2020. Pathological role of excessive DNA as a trigger of keratinocyte proliferation in psoriasis. *Clinical and experimental dermatology*. **202** (1): 1-10.
- McKenzie RC** 2000. Selenium, ultraviolet radiation and the skin. *Clinical and experimental dermatology*. **25** (8): 631-636.
- Parisi R, Symmons DP, Griffiths CE & Ashcroft DM** 2013. Global epidemiology of psoriasis: a

- systematic review of incidence and prevalence. *Journal of investigative dermatology*. **133** (2): 377-385.
- Pi J, et al.** 2013. Pathway of cytotoxicity induced by folic acid modified selenium nanoparticles in MCF-7 cells. *Applied microbiology and biotechnology*. **97** (3): 1051-1062.
- Rafferty TS, Walker C, Hunter JA, Beckett GJ & McKenzie RC** 2002. Inhibition of ultraviolet B radiation-induced interleukin 10 expression in murine keratinocytes by selenium compounds. *British journal of dermatology*. **146** (3): 485-489.
- Rayman MP** 2000. The importance of selenium to human health. *Lancet (London, England)*. **356** (9225): 233-241.
- Ricketts JR, Rothe MJ & Grant-Kels JM** 2010. Nutrition and psoriasis. *Clinics in dermatology*. **28** (6): 615-626.
- Serwin AB, Wasowicz W & Chodynicka B** 2006. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. *Nutrition*. **22** (9): 860-864.
- Serwin AB, Wasowicz W, Gromadzinska J & Chodynicka B** 2003. Selenium status in psoriasis and its relations to the duration and severity of the disease. *Nutrition*. **19** (4): 301-304.
- Toossi P, et al.** 2015. Assessment of serum levels of osteopontin, selenium and prolactin in patients with psoriasis compared with healthy controls, and their association with psoriasis severity. *Clinical and experimental dermatology*. **40** (7): 741-746.
- Verardino GC, Azulay-Abulafia L, Macedo PM & Jeunon T** 2012. Pityriasis amiantacea: clinical-dermatoscopic features and microscopy of hair tufts. *Anais brasileiros de dermatologia*. **87** (1): 142-145.
- Waciewicz M, et al.** 2017. Concentration of selenium, zinc, copper, Cu/Zn ratio, total antioxidant status and c-reactive protein in the serum of patients with psoriasis treated by narrow-band ultraviolet B phototherapy: A case-control study. *Journal of trace elements in medicine and biology*. **44**: 109-114.
- Wadhvani SA, Shedbalkar UU, Singh R & Chopade BA** 2016. Biogenic selenium nanoparticles: current status and future prospects. *Applied microbiology and biotechnology*. **100** (6): 2555-2566.
- Yazdi MH, et al.** 2015. Adjuvant Effect of Biogenic Selenium Nanoparticles Improves the Immune Responses and Survival of Mice Receiving 4T1 Cell Antigens as Vaccine in Breast Cancer Murine Model. *Journal of nanoscience and nanotechnology*. **15** (12): 10165-10172.
- Yildirim M, Inaloz HS, Baysal V & Delibas N** 2003. The role of oxidants and antioxidants in psoriasis. *European academy of dermatology and venereology*. **17** (1): 34-36.
- Zuccotti E, et al.** 2018. Nutritional strategies for psoriasis: current scientific evidence in clinical trials. *European review for medical and pharmacological sciences*. **22** (23): 8537-8551.